Insider Selling: Illumina (NASDAQ:ILMN) SVP Sells $97,328.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Up 2.3%

Shares of ILMN stock opened at $141.88 on Friday. The business’s 50 day moving average is $126.86 and its two-hundred day moving average is $127.86. Illumina, Inc. has a twelve month low of $75.24 and a twelve month high of $155.53. The company has a market capitalization of $21.47 billion, a P/E ratio of 25.80, a price-to-earnings-growth ratio of 2.35 and a beta of 1.42. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the business posted $0.97 EPS. The company’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ILMN shares. Canaccord Genuity Group decreased their price target on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Barclays lifted their price target on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. lifted their price target on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Piper Sandler decreased their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Finally, Stifel Nicolaus lifted their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $131.06.

Hedge Funds Weigh In On Illumina

Several hedge funds and other institutional investors have recently bought and sold shares of ILMN. JPMorgan Chase & Co. boosted its stake in shares of Illumina by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after acquiring an additional 124,246 shares during the last quarter. Elo Mutual Pension Insurance Co acquired a new stake in shares of Illumina during the third quarter valued at $2,319,000. Caprock Group LLC acquired a new stake in shares of Illumina during the third quarter valued at $1,479,000. Nordea Investment Management AB boosted its stake in shares of Illumina by 148.6% during the third quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock valued at $3,024,000 after acquiring an additional 19,519 shares during the last quarter. Finally, Rakuten Investment Management Inc. acquired a new stake in shares of Illumina during the third quarter valued at $861,000. 89.42% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.